The St. Louis Cardinals and the Toronto Blue Jays have agreed to terms to trade 3B-R Troy Glaus for Scott Rolen. Because both players are damaged, former All-Star third basemen with no-trade clauses, it makes for a difficult trade to break down, namely to pick a winner. Perhaps, as what is being called a “challenge trade,” the only winners are Rolen and Glaus, who both needed a change of scenery, but that’s no fun. I’ve put a lot of thought into this one and decided with a trade as close as this one, it makes sense to break it down by offensive and defensive potential, the new ballparks (each player will now play in), health concerns and financial considerations.
The foremost concern for both players is their health. Glaus has been affected by his foot injury, plantar fasciitis and a long history of back problems that were exacerbated by playing on turf in Toronto. He will benefit from a move to grass, which was the reason he requested a trade to begin with. Baseball Prospectus’ Will Carroll had this to say:
“According to sources, Glaus had a nerve problem that was painful but not serious. He had surgery to decompress the nerve causing the pain due to plantar fasciitis. Remember, the Cards have good experience with managing plantar fasciitis—they’ve been able to keep Albert Pujols on the field despite the condition, and Pujols has continued to produce due to some advanced techniques and plain old hard work.”
Rolen has been plagued by an arthritic shoulder that has sapped him of his power and most of his hitting ability. Again, Carroll weighs in on Rolen:
“Rolen’s arthritic condition is going to come back, but his most recent procedure shouldn’t be dissimilar to the last one in terms of results: he’ll be okay for a while, but the time will come when the shoulder will start to tighten up. At that point, Rolen’s going to have to take a hard look at a needle full of cortisone and the rest of his life after baseball. The question is if the Jays medical staff, among the best in the business, can control the symptoms and bring back some of Rolen’s power that’s been lost to the injury.”
Both players have had to deal with injuries but as far as offensive performance goes, Rolen seems to have been more affected offensively by his injury hitting only .265/.331/.398 with 8 home runs in 398 AB in 2007 after a promising 2006. Glaus was limited to 385 AB in 2007, but still managed to hit .262/.366/.473 with 20 home runs. Still, Rogers Centre in Toronto played as more of a hitters park than the new Busch Stadium. A closer look reveals this as Glaus hit .282/.402/.481 at home and .249/.341/.467 on the road. Meanwhile, Rolen hit .243/.319/.366 and a more respectable .289/.344/.432 on the road. Even with a change of scenery, Rolen may not be able to hit for as much power as he once did, but a solid boost to his batting average and some doubles should be more than possible. Glaus will need to keep his power stroke to retain his value but even in Busch, I would still pick Glaus to outperform Rolen.
Defensively, there is no comparison. Rolen has consistently rated as one of the best at third. Even with his injury, he still played +16 FRAA (fielding runs over the average third baseman), keeping his WARP1 at 4.1 despite his meager hitting. Glaus managed to play +3 FRAA and a 4.0 WARP1, which is good for Glaus who historically is slow and unathletic at the hot corner. It will be Rolen’s consistent defensive contribution that will keep his value reasonably high no matter what he hits.
All in all, because of the defense, it would seem likely that the Blue Jays came out on top in this trade because even in the worst season in Rolen’s career, he still outperformed Glaus overall (barely), but the financial considerations are what make the deal tough to assess.
With Rolen still owed $36 million over the remaining 3 years (left over from a eight-year $90 million contract extension–see, 8-year deals never work out), he is signed though his age 35 season, which is a long time for a player who is already being affected by injury. Glaus, on the other hand, picked up his player option for 2009, and will be paid $23.5 million over two years, signed through his age 33 season. This is probably the single most important factor in what is looking like a close trade and for this very reason, it looks like the Cardinals probably got the better end of the deal.
If Rolen, rejuvenated by the trade, is able to hit his way to a .290/.360/.440 line–and this is a big if–with his usual glovework, he may outperform Glaus. It will take Glaus hitting something like .250/.360/.500 to outperform Rolen. Either way, the Cardinals will be off the hook one season sooner, but health will be the ultimate determinant in this deal.
Talks have been on hold since
Word is the Florida Marlins are